Background: Advanced lung cancer patients are predisposed to thrombosis due to many factors related to the disease and treatment, apart from the genetic and phenotypic factors. We aimed to determine the incidence of thromboembolic events (TEs) in advanced Non-Small Cell Lung Cancer (NSCLC) patients treated with platinum chemotherapy and study the baseline and treatment attributes predicting the onset of such events. Method: We evaluated advanced NSCLC patients on platinum chemotherapy for predetermined risk factors for thrombosis at baseline and routine visits. Patients with prior thromboembolism were excluded. The baseline patient characteristics were noted and patients were assigned to Khorana risk group as per the Khorana scores. The duration of follow up was until 4 weeks from the last chemotherapy. TEs occurring between the first dose of chemotherapy and 4 weeks after the last dose were considered as related. Predetermined factors associated with thromboembolism were studied in univariate analysis by chi square test. Result: A total of 188 patients were screened, out of which 21 patients were excluded and two patients were lost to follow up. The mean age of was 57.5 years (range 30e79). Majority of the patients were male (83.2%) and either current or former smokers (62.3 %). 69.5% of patients had a normal Body mass Index (BMI) while 13.2 % were overweight (BMI 25-29.9 kg/m 2) and 1.2 % were class I obese (BMI 30-34.9kg/m 2 ). Majority of the patients (78.1%) belonged to the intermediate Khorana group (Risk score 1-2) while 23.0% belonged to high risk (Khorana score of 3) .Of the 165 patients who completed follow up, 67.8% received carboplatin-gemcitabine, 30.3% carboplatin-pemetrexed, 1.2% cisplatin-pemetrexed and 0.6 % carboplatin-paclitaxel. Median duration on platinum was 94 days (range 1-478). TE's occurred in 4.8% of patients. Three patients developed venous pulmonary thromboembolism and 5 patients developed cerebral infarction, out of which 4 had arterial cerebral infarction and one patient had superior sagittal sinus thrombosis. The majority of events (7 out of 8) occurred within 100 days of starting chemotherapy. None of the presumed risk factors were found to be related to TEs on univariate analysis. Conclusion: Despite the lower incidence of TEs in our study, exclusion of patients with prior thrombosis suggests de novo thrombosis on platinum chemotherapy .None of the predetermined risk factors for thrombosis were found to be statistically related to the occurrence of TEs, possibly due to the small number of events and sample size.
Background: Advanced lung cancer patients are predisposed to thrombosis due to many factors related to the disease and treatment, apart from the genetic and phenotypic factors. We aimed to determine the incidence of thromboembolic events (TEs) in advanced Non-Small Cell Lung Cancer (NSCLC) patients treated with platinum chemotherapy and study the baseline and treatment attributes predicting the onset of such events. Method: We evaluated advanced NSCLC patients on platinum chemotherapy for predetermined risk factors for thrombosis at baseline and routine visits. Patients with prior thromboembolism were excluded. The baseline patient characteristics were noted and patients were assigned to Khorana risk group as per the Khorana scores. The duration of follow up was until 4 weeks from the last chemotherapy. TEs occurring between the first dose of chemotherapy and 4 weeks after the last dose were considered as related. Predetermined factors associated with thromboembolism were studied in univariate analysis by chi square test. Result: A total of 188 patients were screened, out of which 21 patients were excluded and two patients were lost to follow up. The mean age of was 57.5 years (range 30e79). Majority of the patients were male (83.2%) and either current or former smokers (62.3 %). 69.5% of patients had a normal Body mass Index (BMI) while 13.2 % were overweight (BMI 25-29.9 kg/m 2) and 1.2 % were class I obese Background: Depletion of skeletal muscle mass (sarcopenia) have been associated with poor prognosis in patients with malignancy. Although CTdetermined skeletal muscle index (muscle area/height 2 , cm/m 2 ) is regarded as a reference standard to evaluate the presence of sarcopenia, it is unclear the agreement of DECT derived images on the quantification of skeletal muscle area (SMA). The purpose of this study to evaluate the agreement of SMA quantification between dual-energy CT (DECT) derived images (virtual non-contrast; VNC and post-contrast weightaverage 120kVp images) and conventional non-contrast CT image. Method: For a total 128 lung cancer (LCA) patients who underwent DECT at the time of diagnosis, SMA were measured using non-contrast CT, and DECT images (post-processed VNC and weight-average 120kVp). Paired T-test was used to compare the quantification results, and intraclass correlation coefficients (ICC) for the agreement between three scan results. Result: The agreement was excellent (ICC¼0.991) between three images. However, SMA was significant higher in VNC (mean±SD, 125.2±23.8cm 2 , p<0.001) and weight-average 120kVP (110.4±22.0cm 2 , p<0.001) in comparison with non-contrast CT (107.4±22.7cm 2 ). When using recently proposed L1 muscle index cutoff (46 cm/m 2 for male, 29 cm/m 2 for female) for sarcopenia, the prevalence of CT-determined sarcopenia is significantly decreased using weight-average 120kVp and VNC to 53.1% and 22.7%, compared with 58.6% using non-contrast CT. Background: Although substantial decrease of FDG uptake on positron emission tomography-computed tomography (PET-CT) holds promise metabolic response, predicting pathologic complete response of lymph nodes still remains challenging. We investigated the potential of CT radiomics features to predict pathologic complete response of lymph nodes showing residual uptake on PET-CT after neoadjuvant concurrent chemoradiotherapy (CCRT) in stage IIIa non-small cell lung cancer (NSCLC). Method: From 2004 through 2013, all consecutive patients who underwent neoadjuvant CCRT for stage IIIa NSCLC, post-treatment PET-CT, and curative operation were included. As for all lymph nodes which showed remaining positive FDG uptake on restaging PET-CT, 161 CT Radiomic features from physical, shape, histogram, texture, regional feature categories were extracted. Positive and negative lymph node metastases were compared with respect to clinicopathologic characteristics as well as CT radiomic features using the Pearson c2 test or the Fisher exact test Multivariate logistic regression was used to explore the predictive model for the the detection of metastatic lymph nodes, for which receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance. Result: Of 237 patients undergoing neoadjuvant CCRT for stage IIIa NSCLC, 135 patients (56.9%) showed residual PET uptake on 177 lymph nodes after treatment. Among those 177 lymph nodes, 70 lymph nodes were proven to be malignant (39.5%, 70 of 177). On multivariate analysis, metastatic lymph nodes were significantly tended to be more squamous cell carcinoma than adenocarcinoma (odds ratio [OR] ¼ 0.370, 95% confidence interval [CI] ¼ 0.190 to 0.722; reference of adenocarcinoma, P value ¼ 0.004) and higher entropy-GLCM (OR ¼ 1.437, 95% CI ¼ 1.147 to 1.802, P value ¼ 0.002), where the predictive model for metastasis showed discrimination performance with an area under the receiver operating characteristic curve (AUC) of 0.770 (95% CI ¼ 0.700 to 0.839, P value < 0.001). Conclusion: Radiomic approach allows for noninvasive detection of lymph node metastases in lymph nodes showing residual PET uptake after treatment in NSCLC Background: As a comprehensive study of large scale and long-term clinical outcomes from a single institution, we are trying to analyze any predictive or prognostic factors for survival outcomes in N2(+) NSCLC patients. The purpose of this study is to investigate the efficacy of clinical, imaging (CT and PET-CT), and pathologic parameters, as a prognostic factor in N2(+) NSCLC patients undergoing tri-modality therapy. Method: We retrospectively reviewed 160 patients with N2(+) NSCLC patients between January 2008 and June 2014. All patients underwent preoperative concurrent chemoradiotherapy (CCRT) (44-45 Gy in 22-25 fractions concurrent with weekly DP chemotherapy) and surgery. Clinical, imaging (CT and PET-CT), and pathologic parameters were analyzed with respects to outcomes. Result: Overall pathologic down-staging and pathologic complete response following preoperative CCRT were achieved in 66 (41.3%) and 13 patients (8.1%), respectively. The median follow-up durations of all patients was 43 months (2w106 months). The 5-year rates of disease-free survival (DFS) and overall survival (OS) were 33.3% and 53.0%, respectively. Pathologic N down-staging (HR 2.604; 95% CI 1.418-4.779; p value¼0.002) was a significant factor for DFS. Histopathology (HR 0.475; 95% CI 0.242-0.930; p ¼0.030), GTV of nodal lesion(s) on pre-RT CT (HR 1.066; 95% CI 1.029-1.104; p <0.001), type of surgery (HR 2.985; 95% CI 1.114-7.997; p ¼0.030), and proportion of viable tumor on cross-section area (HR 0.986; 95% CI 0.973-0.999; p ¼0.034) were significant factors for OS. Neither tumor volume reduction rate (TVRR) nor SUVmax was significant for DFS or OS. Conclusion: In patients with N2(+) NSCLC undergoing tri-modality therapy, we proved that none of the imaging parameters correlated with prognosis, except pretreatment nodal volume. We confirmed that patients with adenocarcinoma showed prominently improved survival and pathologic N down-staging was a most important pathologic parameter as a prognosticator. Keywords: non-small cell lung cancer, Stage IIIA, prognostic factor P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort A. Klein, 1 I. Herr, 1 S. Maclachlan, 2 D. Potter 3 1 Astra Zeneca, Gaithersburg, MD/US, 2 Evidera, London/GB, 3 Astrazeneca, Gaithersburg, MD/US Background: To describe the demographics, clinical characteristics and treatment sequencing among a real-world cohort of stage III unresectable non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) in the US. Method: Cancerlinq Discovery Database (CLQ), launched by the American Society of Clinical Oncology (ASCO) in 2016, consists of longitudinal, demographically and geographically diverse data aggregated from oncology practice Electronic Health Record (EHR) databases in the US. This retrospective cohort comprises 324 stage III unresectable NSCLC patients who received concurrent, platinum-based chemoradiation between January 1, 2007 and December 31, 2017 (study period) . A patient was considered unresectable if s/he did not have surgery within 6 months of the stage III diagnosis date (study index date). A patient's follow-up period was defined as the time from study index date until the end of the study period, patient death, or loss to follow up, whichever event occured first. Result: The cohort was mostly male, white, with a mean age of 66.86 years at index date. Nearly all patients of the cohort (93.57%) had an initial diagnosis of stage III (75.31% IIIA, 2.78% IIIB); 2.47% had an initial stage I diagnosis and 4.00% had an initial diagnosis of stage II. The most common histology was squamous cell carcinoma (46.61%), followed by adenocarcinoma (41.05%). Curation related to clinical characteristics (eg ECOG status, smoking status and other comorbidities) are ongoing, so they are largely missing at this time. During the mean follow-up time of 26.64 months, the cohort received 1.60 lines of therapy (LOT). The most common treatment sequence during the follow-up period consisted of platinum therapy +CRT (82.72%); almost 10% of patients received platinum therapy +CRT, followed by immuno-oncology (IO) therapy. Approximately 38.30% of patients progressed to line of therapy 2 (LOT2) and 29.84% progressed to line of therapy 3 (LOT3), with nearly 18% of patients receiving IO therapy during LOT2 or LOT3. Conclusion: This exploratory analysis of a stage III unresectable NSCLC cohort is descriptive in nature and suggests that the CLQ Discovery Database can be used to construct generalizable cancer cohorts. Future analyses will focus on validation of CLQ as a realworld data source, using findings from other retrospective, observational studies conducted by AstraZeneca as a benchmark. Background: Lung cancer is the leading cause of cancer morbidity and mortality, both of which imply that its burden may be high upon the health services and society. The purpose of this study is to present an economic analysis of the actual care costs of lung cancer which will allow comparison with, and verification of, cost estimates that were developed through modelling and opinion. Method: A chart review was conducted of incident cases of all patients with newly diagnosed lung cancer during 2015 in the Department of Respiratory Medicine, Gävle Hospital. Cases were censored at two years from the date of diagnosis. Data was retrospectively collected from patient charts. This data included patient characteristics, tumour characteristics, treatment details, adverse events, survival and resource use. Relevant clinical and health utilization data were collected. Health utilization data included hospital and institutional outpatient (ie, ambulatory clinic) costs. The present analysis was performed from the economic perspective of the health care institution. Result: A total of more than 13 000 health service events were captured. Laboratory tests, diagnostic imaging and ambulatory visits constituted 86% of the service events while patient admissions and therapy constituted 76% of the costs. The vast majority of overall costs occurred just before, or within, three months of diagnosis. The cost for imaging was 344042 USD and for diagnostic procedures was 204272 USD. The total cost for chemotherapy was 651879 USD. More data will be presented during the conference. Conclusion: The results agree with the literature that the majority of lung cancer case costs are realized around the date of diagnosis (ie, early phase). The present study illustrates Swedish health care system lung cancer case costs based on actual care received .The majority of the costs occurred soon after diagnosis. These results gave an assessment of all persons treated, the course of the treatment and, thus, is an accurate assessment of costs for policy-making purposes. Keywords: Lung cancer, cost effectiveness, health economic P2.01-60 Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector TM in Metastatic NSCLC Chemotherapy Patients
